【pseudovirus】CHIKV

产品中心 > Cell lines > pseudovirus

【TAA】ITGB1

产品中心 > Cell lines > TAA

【Cytokines】GM-CSF

产品中心 > Proteins > Cytokines

【Immunotherapy target】NKG2D

产品中心 > Proteins > Immunotherapy target

【Immunotherapy target】MICA:MICB

产品中心 > Proteins > Immunotherapy target

【Cell lines】PRRs

产品中心 > Cell lines

【PRRs】NLRP3

产品中心 > Cell lines > PRRs

【GPCR】CMKLR1(ChemR23)

产品中心 > Cell lines > GPCR

【Insights】CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

2024-09-23

【Insights】CD40: UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

2024-09-25

【Insights】IL-17: UCB presents new 4-year data for BIMZELX[®](bimekizumab) in moderate to severe plaque psoriasis at EADV 2024

2024-09-25

【Insights】PD-1/VEGF：GlycoMimetics enters into acquisition agreement with Crescent biopharma

2024-11-01

【Insights】CD19/CD20/CD3：GSK enters agreement to acquire CMG1A46 from Chimagen Bioscience

2024-11-01

【Insights】BTK：Sanofi Announces Positive Data from Phase III Study of BTK Inhibitor ITP

2024-11-06

【Insights】GLP-1R/GCGR/GIPR: Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis

2024-11-06

【Insights】AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2024-11-08

【Insights】HER2: FDA Approves Application for Phase I Clinical Trial of Paragon HER2 ADC for Solid Tumours

2024-11-08

【Insights】PD-1/VEGF BsAb : MSD Enters into Exclusive Global License for LM-299 from LaNova Medicines Ltd.

2024-11-19

【Insights】IL-23：Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra

2024-11-19

【Insights】GLP-1：Amgen’s MariTide Demonstrates 20% Weight Loss

2024-11-28